What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2025-05-14 compared with 2024-11-13 · 437 added, 226 removed, 26 unchanged (96% of the section changed)

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and the other financial information included elsewhere in this Quarterly Report.

This discussion contains forward-looking statements that involve risks and uncertainties.

Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report, particularly those under “Risk Factors.”

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties, and other factors, which may be beyond our control, and which may cause our actual results, performance, or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements.

All statements other than statements of historical fact are statements that could be forward-looking statements.

You can identify these forward-looking statements through our use of words such as “may,” “can,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential” and other similar words and expressions of the future.

There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us.

following discussion and analysis of our financial condition and results of operations should be read together with our financial statements

and the related notes and the other financial information included elsewhere in this Quarterly Report.

This discussion contains forward-looking

statements that involve risks and uncertainties.

Our actual results could differ materially from those anticipated in these forward-looking

statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report, particularly those

under “Risk Factors.”

NOTE REGARDING FORWARD-LOOKING STATEMENTS

Quarterly Report contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation

Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,

Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations,

assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties, and other factors, which

may be beyond our control, and which may cause our actual results, performance, or achievements to be materially different from future

results, performance or achievements expressed or implied by such forward-looking statements.

All statements other than statements of

historical fact are statements that could be forward-looking statements.

You can identify these forward-looking statements through our

use of words such as “may,” “can,” “anticipate,” “assume,” “should,” “indicate,”

“would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,”

“continue,” “plan,” “point to,” “project,” “predict,” “could,”

“intend,” “target,” “potential” and other similar words and expressions of the future.

are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking

statement made by us.

These factors include, but are not limited to:

our lack of operating history;

the expectation that we will incur significant operating losses for the foreseeable future and will need significant additional capital;

our current and future capital requirements to support our development and commercialization efforts for our product candidates and our ability to satisfy our capital needs;

our dependence on our product candidates, which are still in various stages of clinical development;

our ability to acquire sufficient quantities of raw material needed to manufacture our drug product;

our, or that of our third-party manufacturers, ability to manufacture cGMP quantities of our product candidates as required for pre-clinical and clinical trials and, subsequently, our ability to manufacture commercial quantities of our product candidates;

our ability to complete required clinical trials for our product candidates and obtain approval from the FDA or other regulatory agencies in different jurisdictions;

our lack of a sales and marketing organization and our ability to commercialize our product candidates if we obtain regulatory approval;

our dependence on third parties to manufacture our product candidates;

our reliance on third-party CROs to conduct our clinical trials;

our ability to maintain or protect the validity of our intellectual property;

our ability to internally develop new inventions and intellectual property;

interpretations of current laws and the passages of future laws;

acceptance of our business model by investors;

the accuracy of our estimates regarding expenses and capital requirements;

our ability to adequately support organizational and business growth;

other factors discussed in our most recent Annual Report on Form 10-K.

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipate in our forward-looking statements.

lack of operating history;

expectation that we will incur significant operating losses for the foreseeable future and will need significant additional capital;

current and future capital requirements to support our development and commercialization efforts for our product candidates and our

ability to satisfy our capital needs;

dependence on our product candidates, which are still in various stages of clinical development;

ability to acquire sufficient quantities of raw material needed to manufacture our drug product;

or that of our third-party manufacturers, ability to manufacture cGMP quantities of our product candidates as required for pre-clinical

and clinical trials and, subsequently, our ability to manufacture commercial quantities of our product candidates;

ability to complete required clinical trials for our product candidates and obtain approval from the FDA or other regulatory agencies

in different jurisdictions;

lack of a sales and marketing organization and our ability to commercialize our product candidates if we obtain regulatory approval;

dependence on third parties to manufacture our product candidates;

reliance on third-party CROs to conduct our clinical trials;

ability to maintain or protect the validity of our intellectual property;

ability to internally develop new inventions and intellectual property;

interpretations

of current laws and the passages of future laws;

of increased trade tariffs, import quotas or other trade restrictions or measures taken by the United States and other countries,

including the recent and potential changes in U.S.

trade policies that have been and may be made by the Trump presidential administration;

of our business model by investors;

accuracy of our estimates regarding expenses and capital requirements;

ability to adequately support organizational and business growth;

factors discussed in our most recent Annual Report on Form 10-K.

foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or

risk factors that we are faced with that may cause our actual results to differ from those anticipate in our forward-looking statements.

Please see “Risk Factors” for additional risks which could adversely impact our business and financial performance.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice.

You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report, or the date of the document incorporated by reference into this report.

We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

We have expressed our expectations, beliefs and projections in good faith, and we believe they have a reasonable basis.

However, we cannot assure you that our expectations, beliefs, or projections will result or be achieved or accomplished.

We are a late-stage medical dermatology company focused on identifying, developing, and commercializing innovative pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases we believe represent significant market opportunities.

Dermatological diseases such as acne vulgaris (or acne), psoriasis vulgaris (or psoriasis), hyperhidrosis, and various aesthetic indications, affect millions of people worldwide each year which may negatively impact their quality of life and emotional well-being.

While there are multiple current treatment options for these indications on the market, we believe that most have significant drawbacks, including underwhelming efficacy, cumbersome application regimens and varying negative side effects, all of which we believe lead to decreased patient compliance.

A majority of these indications are first treated with topical therapy;

however, many patients frequently switch treatments or discontinue treatment altogether due to patient dissatisfaction.

This is primarily due to slow and modest response rates, early onset of negative side effects, daily application schedules and long duration of therapy.

Given the limitations with current topical therapies, we believe there is a significant opportunity to address the needs of frustrated patients searching for topical products that satisfy their dermatological and lifestyle needs.

Our two product candidates, DMT310 and DMT410, both incorporate our proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions.

Our Spongilla technology is derived from a naturally grown freshwater sponge, Spongilla lacustris or Spongilla , which is processed into a powder that is mixed with a fluidizing agent immediately prior to application to form an easily applicable paste.

Spongilla is a unique freshwater sponge that only grows in commercial quantities in select regions of the world and under specific environmental conditions, all of which give it its distinctive anti-microbial, anti-inflammatory, and mechanical properties.

The combination of these environmental conditions, the proprietary harvesting protocols developed with our exclusive supplier, and our post-harvest processing procedures produce a pharmaceutical product candidate that optimizes the mechanical components as well as the chemical components of the sponge to create a product candidate with multiple mechanisms of action for the treatment of medical and aesthetic skin diseases and conditions.

We believe our Spongilla technology platform will enable us to develop and formulate singular and combination products that are able to target the topical delivery of chemical compounds into the dermis for a variety of dermatology indications.

We believe the combination of Spongilla’s mechanical and chemical components (which we believe have demonstrated, in-vitro , anti-microbial and anti-inflammatory properties), add to the versatility of our Spongilla technology platform’s effectiveness as a singular product, in the treatment of a wide variety of medical skin diseases like acne and psoriasis.

We also believe the mechanical properties of our Spongilla technology allows for the intradermal delivery of a variety of large molecules, like botulinum toxins, monoclonal antibodies, or dermal fillers, to target treatment sites, through topical application without the need for needles.

Our lead product candidate, DMT310, is intended to utilize our Spongilla technology for the once weekly treatment of a variety of skin diseases, with our initial focus being the treatment of acne vulgaris, which has a U.S.

market size of approximately 30 million diagnosed patients.

We recently initiated a Phase 3 program of DMT310 in moderate-to-severe acne.

Both studies will be double-blinded, randomized, placebo-controlled, and enroll up to 550 patients, age 9 years or older across sites in the United States and Latin America.

The primary endpoints include absolute reduction in inflammatory and noninflammatory lesions and the improvement in investigators global assessment (“IGA”) of acne, which are the same endpoints used in our Phase 2b study of DMT310 for moderate-to-severe acne.

Patients will be treated once a week for 12 weeks with either DMT310 or placebo and will be evaluated monthly.

The second Phase 3 study will be followed by a long-term extension study.

We recently announced enrollment of 50% of the total expected patients in the STAR-1 study and we expect to have top-line results from the first Phase 3 study in the first quarter of 2025.

Previously, DMT310 has shown its ability to treat the multiple causes of acne in a Phase 2b study where we initially saw a 45% reduction in inflammatory lesions after four treatments, with DMT310 achieving statistically significant improvements at all time points for all three primary endpoints throughout the study (reduction in inflammatory lesions, reduction in non-inflammatory lesions, and improvement in IGA).

In addition, based on the multiple mechanisms of action and anti-inflammatory effect seen with the DMT310 acne trial, we completed a Phase 1b proof of concept, or POC, trial in psoriasis where we saw encouraging results warranting further investigation.

DMT310 consists of two grams of powder processed from the naturally grown freshwater sponge, Spongilla lacustris.

The patient mixes the powder with a fluidizing agent (3% hydrogen peroxide) immediately prior to application by the patient to form an easy-to-apply paste.

The paste is applied like a mud mask and is left on the skin for approximately ten to fifteen minutes, after which time it is washed off with water.

Due to the unique combination of DMT310’s mechanical components and chemical components, and based on our Phase 2 acne data, we believe patients will only need to apply DMT310 once weekly to produce the desired treatment effect.

The mechanical components of the Spongilla powder consist of many microscopic siliceous, needle-like spicules that, when massaged into the skin, penetrate the stratum corneum (the skin’s outermost protective layer) and create microchannels into the dermis where pro-inflammatory cytokines and bacteria reside.

We believe that the penetration of the spicules also leads to the opening of microchannels, which allow oxygen to enter pilosebaceous glands, helping to kill C.

forward-looking statements are expressly qualified in their entirety by this cautionary notice.

You are cautioned not to place undue

reliance on any forward-looking statements, which speak only as of the date of this report, or the date of the document incorporated

by reference into this report.

We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the

forward-looking statements, whether as a result of new information, future events or otherwise.

We have expressed our expectations, beliefs

and projections in good faith, and we believe they have a reasonable basis.

However, we cannot assure you that our expectations, beliefs,

or projections will result or be achieved or accomplished.

are a late-stage medical dermatology company focused on identifying, developing, and commercializing innovative pharmaceutical product

candidates for the treatment of medical skin diseases and aesthetic applications we believe represent significant market opportunities.

Dermatological

diseases such as acne vulgaris (or acne), psoriasis vulgaris (or psoriasis), hyperhidrosis, and various aesthetic indications, affect

millions of people worldwide each year which may negatively impact their quality of life and emotional well-being.

While there are multiple

current treatment options for these indications on the market, we believe that most have significant drawbacks, including underwhelming

efficacy, cumbersome application regimens and varying negative side effects, all of which we believe lead to decreased patient compliance.

A majority of these indications are first treated with topical therapies, however, many patients frequently switch treatments or discontinue

treatment altogether due to patient dissatisfaction.

This is primarily due to slow and modest response rates, early tolerability issues,

once or twice daily application schedules and long duration of therapy.

Given the limitations with current topical therapies, we believe

there is a significant opportunity to address the needs of frustrated patients searching for topical products that satisfy their dermatological

and lifestyle needs.

two product candidates, XYNGARI™ (formerly DMT310) and DMT410, both incorporate our proprietary, multifaceted, Spongilla technology

to topically treat a variety of dermatological conditions.

Our Spongilla technology is derived from a naturally grown freshwater

sponge, Spongilla lacustris or Spongilla , which is processed into a powder that is mixed with a fluidizing agent immediately

prior to application to form an easily applicable paste.

Spongilla is a unique freshwater sponge that only grows in commercial

quantities in select regions of the world and under specific environmental conditions, all of which give it its distinctive anti-microbial,

anti-inflammatory, and mechanical properties.

The combination of these environmental conditions, the proprietary harvesting protocols

developed with our exclusive supplier, and our post-harvest processing procedures produce a pharmaceutical product candidate that optimizes

the mechanical components as well as the chemical components of the sponge to create a product candidate with multiple mechanisms of

action for the treatment of inflammatory skin diseases and aesthetic applications.

believe our Spongilla technology platform will enable us to develop XYNGARI TM as either a single, stand-alone agent,

or used together with other dermatology products to target the topical delivery of chemical compounds into the dermis for a variety of

dermatology indications.

We believe the combination of Spongilla’s mechanical and chemical components (which we believe

have demonstrated, in-vitro , anti-microbial and anti-inflammatory properties), add to the versatility of our Spongilla

technology platform’s effectiveness as a singular product, in the treatment of a wide variety of medical skin diseases like acne

and psoriasis.

We also believe the mechanical properties of our Spongilla technology allows for the intradermal delivery of a

variety of large molecules, like botulinum toxins, monoclonal antibodies, or dermal fillers, to targeted treatment sites, through topical

application without the need for needles.

lead product candidate, XYNGARI™, is intended to utilize our Spongilla technology for the once weekly treatment of a variety

of skin diseases, with our initial focus being the treatment of acne, which has a U.S.

market size of approximately 30 million patients

seeking treatment.

In March 2025, we announced that our XYNGARI™ Phase 3 S pongilla T reatment of A cne R esearch

(STAR-1) trial topline data met all co-primary endpoints at week 12.

XYNGARI™ demonstrated highly statistically significant difference

compared with placebo for all primary endpoints after 12 weeks of once weekly treatments.

XYNGARI™ patients saw a rapid and sustained

therapeutics treatment effect in absolute reduction in inflammatory lesion counts with a -11.4 lesion reduction at week four, -14.7 lesions

reduction at week 8, and -16.8 lesion reduction at week 12 compared to -8.6, -10.9, and -13.1 lesion reduction for placebo at weeks 4,

8, and 12, respectively.

XYNGARI™ patients also saw a rapid and sustained therapeutics treatment effect in absolute reduction in

noninflammatory lesion counts with a -12.4 lesion reduction at week four, -15 lesions reduction at week 8, and -17.3 lesion reduction

at week 12 compared to -8.8, -10.4, and -12.4 lesion reduction for placebo at weeks 4, 8, and 12, respectively.

Lastly, we observed a

sustained therapeutics treatment effect in the investigator’s global assessment of acne with a 11.9% of XYNGARI™ patients

being considered a responder at week four, 21.6% of XYNGARI™ patients being considered a responder at week 8, and 29.4% of XYNGARI™

patients being considered a responder at week 12 compared to 6.2%, 8.0%, and 15.2% of placebo patients being considered a responder at

weeks 4, 8, and 12, respectively.

The Phase 3 STAR-1 trial was double-blind, randomized, placebo controlled, and enrolled 520 patients

with moderate-to-severe acne, age 9 years or older across sites in the United States and Latin America.

The co-primary endpoints included

absolute reduction in inflammatory and noninflammatory lesion counts and the improvement in investigators global assessment (IGA) of

Patients were treated once a week for 12 weeks with either XYNGARI™ or placebo and were evaluated monthly.

We are currently

evaluating the full data set from the STAR-1 trial.

As requested by the FDA, we will have to complete a second Phase 3 trial, STAR-2,

which will be followed by an extension study to follow patients for a 12-month total treatment period.

The STAR-2 trial will include

a near identical trial design to the STAR-1 trial and is planned to begin by the end of 2025.

Previously XYNGARI™ has shown its

ability to treat the multiple causes of acne in a Phase 2b study where we initially saw a 45% reduction in inflammatory lesions after

four treatments, with XYNGARI™ achieving statistically significant improvements at all time points for all three primary endpoints

throughout the study (reduction in inflammatory lesions, reduction in non-inflammatory lesions, and improvement in IGA).

based on the multiple mechanisms of action and anti-inflammatory effect seen with the XYNGARI™ acne trial, we completed a Phase

1b proof of concept, or POC, trial in psoriasis where we saw encouraging results warranting further investigation upon our receipt of

adequate funding.

consists of two grams of powder processed from the naturally grown freshwater sponge, Spongilla lacustris.

The patient mixes the

powder with a fluidizing agent (3% hydrogen peroxide) immediately prior to application to form an easy-to-apply paste.

The paste is applied

like a mud mask and is left on the skin for approximately ten to fifteen minutes, after which time it is washed off with water.

the unique combination of XYNGARI™’s mechanical components and chemical components, and based on our Phase 2 acne data, we

believe patients will only need to apply XYNGARI™ once weekly to produce the desired treatment effect.

The mechanical components

of the Spongilla powder consist of many microscopic siliceous, needle-like spicules that, when massaged into the skin, penetrate

the stratum corneum (the skin’s outermost protective layer) and create microchannels into the dermis where pro-inflammatory cytokines

and bacteria reside.

We believe that the penetration of the spicules also leads to the opening of microchannels, which allow oxygen to

enter pilosebaceous glands, helping to kill C.

acnes , which grow in an anaerobic (without oxygen) environment ( C.

acnes is the bacteria that cause inflammatory lesions in acne patients).

The spicules also cause rejuvenation of the top layer of dead skin, thereby increasing collagen production.

Additionally, we believe the newly created microchannels provide a conduit for DMT310’s naturally occurring chemical compounds to be delivered to the dermis and pilosebaceous glands, helping to kill the C.

acnes and fight inflammation .

In addition to these anti-microbial compounds, DMT310 also appears to have anti-inflammatory chemical compounds, as demonstrated in in vitro experiments, that inhibit inflammation through the reduction of C.acnes stimulated IL-8 production and by inhibiting IL-17A and IL-17F expression in human cell lines.

Also, during in vitro studies of DMT310’s organic compounds, we observed the inhibition of the lipogenesis of sebocytes, which may translate to a reduction in sebum (an oily and waxy substance produced by the human body’s sebaceous glands) production and the oiliness of the skin in patients, which was observed by a number of clinical investigators in our Phase 2 acne studies.

We believe the combination of these biological and mechanical effects could be important factors in treating multiple inflammatory skin diseases, as seen in our clinical trials.

Our second product candidate utilizing our Spongilla technology is DMT410, our combination treatment.

DMT410 is intended to consist of one treatment of our proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.

Currently, BOTOX®, is the only approved botulinum toxin to be delivered to the dermis by intradermal injections, which can be painful for the patient and time-consuming for the physician.

However, we believe DMT410’s ability to topically deliver a botulinum toxin into the dermis could have similar levels of efficacy to intradermal injections of botulinum toxin, with fewer tolerability issues, and a quicker application time, possibly replacing the need for intradermal injections.

We first tested DMT410 with BOTOX® in a Phase 1 POC trial of axillary hyperhidrosis patients, which saw 80% of patients achieve a reduction in gravimetric sweat production greater than 50% four weeks after a single treatment.

With almost 40% of the hyperhidrosis market currently being treated with intradermal injections of BOTOX®, we believe there could be significant opportunity for DMT410 to break into this market and replace intradermal injections of botulinum toxin with a topical delivery option.

Based on DMT410’s ability to effectively deliver botulinum toxin to the dermis as observed in the Phase 1 axillary hyperhidrosis trial, we also conducted a Phase 1 POC trial of DMT410 with BOTOX® for the treatment of multiple aesthetic skin conditions, including reduction of pore size, sebum production, and fine lines, among others.

In November 2021, we announced top-line results from this trial, where we saw promising data that we believe warrants further investigation of DMT410.

Given that BOTOX® is a Type A toxin, and acts through a similar pathway as other Type A botulinum toxins, we are discussing partnering opportunities with multiple companies that have a botulinum toxin type A to move our DMT410 program into additional clinical studies.

We have a limited operating history.

Since our inception, our operations have focused on developing DMT310 and DMT410, organizing and staffing our company, raising capital, establishing our supply chain and manufacturing processes, further characterizing the multiple mechanisms of action of our Spongilla technology, building an intellectual property portfolio, and conducting non-clinical and clinical trials.

the bacteria that cause inflammatory lesions in acne patients).

The spicules also cause turnover of the top layer of dead skin, thereby

increasing collagen production resulting in skin rejuvenation.

Additionally, we believe the newly created microchannels provide a conduit

for XYNGARI™’s naturally occurring chemical compounds to be delivered to the dermis and pilosebaceous glands, helping to

acnes and reduce inflammation .

In addition to anti-microbial compounds, XYNGARI™ also appears to have anti-inflammatory

chemical compounds, as demonstrated during in vitro experiments, that inhibit inflammation through the reduction of C.acnes

stimulated IL-8 production and by inhibiting IL-17A and IL-17F expression in human cell lines.

Also, during in vitro studies

of XYNGARI™’s organic compounds, we observed the inhibition of the lipogenesis of sebocytes, which may translate to a reduction

in sebum (an oily and waxy substance produced by the human body’s sebaceous glands) production and the oiliness of the skin in

patients, which was observed by a number of clinical investigators in our Phase 2 acne studies.

We believe the combination of these biological

and mechanical effects could be important factors in treating multiple inflammatory skin diseases, as seen in our clinical trials.

second product candidate utilizing our Spongilla technology is DMT410.

DMT410 is intended to consist of one treatment of our proprietary

sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.

Currently, botulinum toxin is only

approved to be delivered to the dermis by intradermal injections, which can be painful for the patient and time-consuming for the physician.

However, we believe DMT410’s ability to topically deliver botulinum toxin into the dermis could have similar levels of efficacy

to existing delivery techniques, with fewer tolerability issues, and a quicker application time, possibly replacing the need for intradermal

We first tested DMT410 in a Phase 1 POC trial in primary axillary hyperhidrosis patients where we observed 80% of patients

achieving a reduction in gravimetric sweat production greater than 50% four weeks after a single treatment.

With almost 40% of the hyperhidrosis

market currently being treated with intradermal injections of botulinum toxin, we believe there could be significant opportunity for

DMT410 to break into this market and replace intradermal injections of botulinum toxin.

Based on DMT410’s ability to effectively

deliver botulinum toxin to the dermis as observed in the Phase 1 axillary hyperhidrosis trial, we also conducted a Phase 1 POC trial

of DMT410 for the treatment of multiple aesthetic skin conditions, including reduction of pore size, sebum production, and fine lines,

among others.

In November 2021, we announced top-line results from this trial, where we saw promising data that we believed warranted

further investigation of DMT410.

January 17, 2025, we entered into a Clinical Trial Collaboration Agreement (the “Collaboration Agreement”) with Revance Therapeutics,

(“Revance”) where we intend to initiate a Phase 2a clinical trial to evaluate the topical application of XYNGARI™

followed by the topical application of DAXXIFY® for the treatment of primary axillary hyperhidrosis.

The Phase 2a clinical trial

is anticipated to evaluate the efficacy, safety, and tolerability of XYNGARI™ and DAXXIFY® versus XYNGARI™ and placebo

in patients with moderate-to-severe axillary hyperhidrosis for 16 weeks.

The trial is anticipated to be randomized (1:1:1:1), double-blind,

placebo-controlled, enrolling approximately 48 patients across sites in the United States.

The endpoints are intended to be the percent

of patients with greater than 50% reduction in gravimetrically measured sweat production from baseline, the percent of patients with

gravimetric sweat production less than 50mg, and the mean absolute change from baseline in gravimetrically measured.

have a limited operating history.

Since our inception, our operations have focused on developing XYNGARI™ and DMT410, organizing

and staffing our company, raising capital, establishing our supply chain and manufacturing processes, further characterizing the multiple

mechanisms of action of our Spongilla technology, building an intellectual property portfolio, and conducting non-clinical and

clinical trials.

We do not have any product candidates approved for marketing and have not generated any revenue from product sales.

We have funded our operations primarily through the sale of our equity securities and debt securities.

Since inception, we have raised an aggregate of approximately $68.8 million of gross proceeds from the sale of our debt and equity securities.

We have not generated any revenue to date and have incurred significant operating losses.

Our net losses were $3.2 million and $1.7 million for the three months ended September 30, 2024, and 2023, respectively, and our net losses were $9.1 million and $5.7 million for the nine months ended September 30, 2024, and 2023, respectively.

As of September 30, 2024, we had an accumulated deficit of $62.5 million.

Since inception, we have raised

an aggregate of approximately $77.5 million of gross proceeds from the sale of our debt and equity securities.

have not generated any revenue to date and have incurred significant operating losses.

Our net losses were $2.3 million and $3.1 million

for the three months ended March 31, 2025, and 2024, respectively.

As of March 31, 2025, we had an accumulated deficit of $68.0 million.

We expect to continue to incur significant expenses and operating losses for the foreseeable future.

We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:

complete development of DMT310 for the treatment of acne, including non-clinical studies and Phase 3 clinical trials;

prepare and file for regulatory approval of DMT310 for the treatment of moderate-to-severe acne;

identify a botulinum toxin partner for DMT410 for the treatment of medical and aesthetic skin conditions and diseases;

continue development of DMT410 for the treatment of treatment of aesthetic and medical skin conditions, including Phase 1 and Phase 2 clinical trials;

prepare for commercialization of DMT310, if approved, including the hiring of sales and marketing personnel;

manufacture our product candidates for additional Phase 2 and Phase 3 trials and commercial sale;

hire additional research and development and selling, general and administrative personnel;

maintain, expand, and protect our intellectual property portfolio; and

incur additional costs associated with operating as a public company.

We will need additional financing to support our operations.

We may seek to fund our operations through public or private equity or debt financings or other sources.

We anticipate that our expenses

will increase significantly in connection with our ongoing activities, as we:

development of XYNGARI™ for the treatment of acne, including non-clinical studies and the second Phase 3 clinical trial;

and file for regulatory approval of XYNGARI™ for the treatment of moderate-to-severe acne;

a botulinum toxin partner for DMT410 for the treatment of medical and aesthetic skin conditions and diseases;

development of DMT410 for the treatment of treatment of aesthetic and medical skin conditions, including Phase 1 and Phase 2 clinical

for commercialization of XYNGARI™, if approved, including the hiring of sales and marketing personnel;

our product candidates for additional Phase 2 and Phase 3 trials and commercial sale;

additional research and development and selling, general and administrative personnel;

expand, and protect our intellectual property portfolio; and

additional costs associated with operating as a public company.

will need additional financing to support our operations.

We may seek to fund our operations through public or private equity or debt

financings or other sources.

Adequate additional financing may not be available to us on acceptable terms, or at all.

Our failure to raise capital when needed or on favorable terms would have a negative impact on our financial condition and our ability to pursue our business strategy.

Our failure to

raise capital when needed or on favorable terms would have a negative impact on our financial condition and our ability to pursue our

business strategy.

We will need to generate significant revenues to achieve profitability, and we may never do so.

Recent Developments

In July 2024, we reached the 50% patient enrollment milestone in the first of two Phase 3 clinical trials of DMT310 in moderate-to-severe acne.

We expect to receive top-line results from the first Phase 3 trial, referred to as STAR-1, in the first quarter of 2025.

Both Phase 3 studies will be double-blinded, randomized, placebo-controlled, and enroll up to 550 patients, age 9 years or older across sites in the United States and Latin America.

The primary endpoints include absolute reduction in inflammatory and noninflammatory lesions and the improvement in investigators global assessment (IGA) of acne.

Patients will be treated once a week for 12 weeks with either DMT310 or placebo and will be evaluated monthly.

ATM Agreement

In June 2024, we entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C.

Wainwright &Co., LLC (“HCW”), as sales agent, pursuant to which we may offer and sell, from time to time through HCW, shares of our common stock for aggregate proceeds of up to $1,662,761 (upon the terms and subject to the conditions and limitations set forth in the ATM Agreement).

In the nine months ended September 30, 2024, we sold 550,024 shares of common stock under the ATM Agreement, for net proceeds of $1.5 million, after deducting $0.1 million of compensation to HCW and other administration fees.

Critical Accounting Policies and Use of Estimates

We have based our management’s discussion and analysis of financial condition and results of operations on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States.

The preparation of these financial statements requires us to make estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as expenses during the reporting periods.

On an ongoing basis, we evaluate our estimates and judgments, including those related to clinical development expenses.

We base our estimates on historical experience and on various other factors that we believe to be appropriate under the circumstances.

Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully discussed in Note 2 - Summary of Significant Accounting Policies to our unaudited financial statements contained within this Form 10-Q, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements.

Research and Development Expenses

We rely on third parties to conduct our clinical studies and to provide services, including data management, statistical analysis, and electronic compilation.

Once our clinical trials begin, at the end of each reporting period, we will compare the payments made to each service provider to the estimated progress towards completion of the related project.

Factors that we will consider in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of our vendors.

These estimates will be subject to change as additional information becomes available.

Depending on the timing of payments to vendors and estimated services provided, we will record net prepaid or accrued expenses related to these costs.

Fluctuations in Operating Results

Our results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future.

We anticipate that our quarterly and annual results of operations will be impacted for the foreseeable future by several factors, including the progress and timing of expenditures related to the development of our product candidates.

Due to these fluctuations, we believe that the period-to-period comparisons of our operating results are not a good indication of our future performance.

Results of Operations

Three Months Ended September 30, 2024, and 2023

The following table summarizes our results of operations for the periods presented:

Three Months Ended September 30,

January 21, 2025, we closed a private placement (the “January 2025 PIPE”) priced at the market under Nasdaq rules, in which

we sold 1,935,412 shares of Common Stock, pre-funded warrants to purchase an aggregate of 72,468 shares of Common Stock with an exercise

price of $0.001 per share (“January 2025 Pre-Funded Warrants”), and 2,007,880 warrants (the “January 2025 PIPE Warrants”)

to purchase up to an aggregate of 2,007,880 shares of Common Stock.

The January 2025 PIPE Warrants have an exercise price of $1.27.

our insiders, including our Chief Executive Officer, Chief Financial Officer and certain members of the our board of directors, participated

in the January 2025 PIPE.

These insiders purchased an aggregate of 1,220,476 shares of Common Stock and January 2025 PIPE Warrants to

purchase up to an aggregate of 1,220,476 shares of Common Stock, for an aggregate purchase price of approximately $1,550,000.

price per share of Common Stock and accompanying January 2025 PIPE Warrant for these insiders was the same as paid by other investors

in the January 2025 PIPE.

In connection with the January 2025 PIPE, we entered into a registration rights agreement with the investor,

pursuant to which we agreed to prepare and file a registration statement with the SEC registering the resale of the shares of Common

Stock underlying the securities sold in the January 2025 PIPE financing.

We filed a Form S-3 on January 30, 2025, which was declared

effective by the SEC on February 5, 2025.

We received net cash proceeds of approximately $2.3 million from the January 2025 PIPE after

deducting underwriters’ discounts and offering expenses of approximately $0.3 million.

During the first quarter of 2025, all of

the January 2025 Pre-Funded Warrants were exercised.

As of March 31, 2025, no January 2025 Pre-Funded Warrants remained outstanding.

March 27, 2025, we announced that our XYNGARI™ Phase 3 STAR-1 trial met all co-primary endpoints by achieving highly statistically

significant difference when compared with placebo after 12 weeks of once weekly treatments.

At week 12, XYNGAR™ achieved IGA success

(2-point change and 0 or 1) in 29.4% of patients vs.

15.2% of patients on placebo (p<0.001), XYNGARI™ saw a -16.8 inflammatory

lesion reduction compared with a -13.1 inflammatory lesion reduction for placebo (p<0.001), and XYNGARI™ saw a -17.3 noninflammatory

lesion reduction compared with a -12.4 noninflammatory lesion reduction for placebo (p<0.001).

Based on this positive data, we plan

initiate the second XYNGARI™ Phase 3 STAR-2 trial by the end of 2025.

March 27, 2025, we entered into an inducement offer letter agreement (the “March 2025 Inducement Letter”) with a holder (the

“Holder”) of certain of our existing warrants to purchase an aggregate of 4,834,470 shares of our common stock.

Such existing

warrants were made up of (i) certain of the May 17, 2024 (the “May 2024 Warrants”), which were issued in two separate series,

having an exercise price of $4.91 per share, and (ii) the September 16, 2024, which were issued in two separate series, having an exercise

price of $1.58 per share (the “September 2024 Warrants” and together with the May 2024 Warrants, the “Existing Warrants”).

Pursuant to the March 2025 Inducement Letter, the Holder agreed to exercise for cash its Existing Warrants at a reduced exercise price

of $1.284 per share in consideration for our agreement to issue in a private placement (i) new Series A common stock purchase warrants

(the “New Series A Warrants”) to purchase up to 4,980,806 shares of Common Stock (the “New Series A Warrant Shares”)

and (ii) new Series B common stock purchase warrants (the “New Series B Warrants” and together with the New Series A Warrants,

the “New Warrants”) to purchase up to 4,688,134 shares of Common Stock (the “New Series B Warrant Shares” and

together with the New Series A Warrant Shares, the “New Warrant Shares”).

We received net proceeds of approximately $5.8

million from the exercise of the Existing Warrants by the Holder, after deducting financial advisor fees and other offering expenses

payable by us.

June 2024, we entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C.

Wainwright &Co., LLC (“HCW”),

as sales agent, pursuant to which we may offer and sell, from time to time through HCW, shares of our common stock for aggregate proceeds

of up to $1,662,761 (upon the terms and subject to the conditions and limitations set forth in the ATM Agreement).

During the three months

ended March 31, 2025, we sold no shares of common stock under the ATM Agreement and have no capacity to sell shares pursuant to the ATM

Agreement remaining.

Accounting Policies and Use of Estimates

have based our management’s discussion and analysis of financial condition and results of operations on our financial statements,

which have been prepared in accordance with accounting principles generally accepted in the United States.

The preparation of these financial

statements requires us to make estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent

assets and liabilities at the date of the financial statements as well as expenses during the reporting periods.

On an ongoing basis,

we evaluate our estimates and judgments, including those related to clinical development expenses.

We base our estimates on historical

experience and on various other factors that we believe to be appropriate under the circumstances.

Actual results may differ from these

estimates under different assumptions or conditions.

our significant accounting policies are more fully discussed in Note 2 - Summary of Significant Accounting Policies to our unaudited

financial statements contained within this Form 10-Q, we believe that the following accounting policies are critical to the process of

making significant judgments and estimates in the preparation of our financial statements.

and Development Expenses

rely on third parties to conduct our clinical studies and to provide services, including data management, statistical analysis, and electronic

Once our clinical trials begin, at the end of each reporting period, we will compare the payments made to each service provider

to the estimated progress towards completion of the related project.

Factors that we will consider in preparing these estimates include

the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of our vendors.

These estimates

will be subject to change as additional information becomes available.

Depending on the timing of payments to vendors and estimated services

provided, we will record net prepaid or accrued expenses related to these costs.

perform an assessment of warrants upon issuance to determine their proper classification in the financial statements based upon the warrant’s

specific terms, in accordance with the authoritative guidance provided in Financial Accounting Standards Board (“FASB”) Accounting

Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) , and ASC 815-40,

Derivatives and Hedging – Contracts in Entity’s Own Equity (“ASC 815-40”) .

The assessment considers whether

the warrants are freestanding financial instruments pursuant to ASC 480 and whether the warrants meet all of the requirements for equity

classification under ASC 815, including whether the warrants are indexed in our own Common Stock and whether the warrant holders could

potentially require cash settlement of the warrants.

issued or modified warrants that meet all the criteria for equity classification, the warrants are required to be recorded as a component

of additional paid-in capital.

For issued or modified warrants that do not meet all the criteria for equity classification, the warrants

are required to be liability-classified and recorded at their initial fair value on the date of issuance and remeasured at fair value

at each balance sheet date thereafter.

We have performed an assessment of all warrants issued and modified and determined that our warrants

are equity classified.

in Operating Results

results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future.

We anticipate that our quarterly and annual results of operations will be impacted for the foreseeable future by several factors, including

the progress and timing of expenditures related to the development of our product candidates.

Due to these fluctuations, we believe that

the period-to-period comparisons of our operating results are not a good indication of our future performance.

of Operations

Months Ended March 31, 2025, and 2024

following table summarizes our results of operations for the periods presented:

Three Months Ended

Operating expenses:

Research and development

General and administrative

Total operating expenses

Losses from operations

Other income and expenses:

Interest income, net

$ (3,173,156 )

$ (1,719,211 )

$ (1,453,945 )

Research and Development Expenses

Research and development expenses increased by $1.5 million from $0.9 million for the three months ended September 30, 2023, to $2.4 million for the three months ended September 30, 2024.

The increase in research and development expenses in the third quarter of 2024 as compared to the same period in 2023 resulted from $1.8 million of increased clinical expenses from the DMT310 STAR-1 acne study initiated in late 2023, offset by $0.3 million of decreased chemistry, manufacturing, and controls, or CMC, expenses.

General and Administrative Expenses

General and administrative expenses decreased by $0.1 million from $0.9 million for the three months ended September 30, 2023, to $0.8 million for the three months ended September 30, 2024.

The decrease in general and administrative expenses in the third quarter of 2024 as compared to the same period of 2023 resulted from $0.1 million in decreased insurance costs.

Other Income and Expenses

Other income and expenses decreased by $40,270 from $92,767 for the three months ended September 30, 2023, to $52,497 for the three months ended September 30, 2024.

The decrease in interest income resulted from less cash and cash equivalents available for earning interest income.

Nine Months Ended September 30, 2024, and 2023

The following table summarizes our results of operations for the periods presented:

Nine Months Ended September 30,

and administrative

operating expenses

Research and development

General and administrative

Total operating expenses

Loss from operations

Other income and expenses:

Interest expense, net

$ (9,136,523 )

Interest income

$ (2,303,587 )

$ (3,134,262 )

Research and Development Expenses

Research and development expenses increased by $3.1 million from $2.9 million for the nine months ended September 30, 2023, to $6.0 million for the nine months ended September 30, 2024.

The increase in research and development expenses resulted from $4.0 million of increased clinical expenses from the DMT310 STAR-1 acne study initiated in late 2023, offset by $0.7 million of decreased chemistry, manufacturing, and controls, or CMC, expenses and $0.2 million of decreased non-clinical expenses.

General and Administrative Expenses

General and administrative expenses increased by $0.4 million from $2.9 million for the nine months ended September 30, 2023, to $3.3 million for the nine months ended September 30, 2024.

This increase resulted from $0.5 million of increased audit fees as well as $0.1 million of increased stock-based compensation, offset by $0.2 million of decreased insurance costs.

Other Income and Expenses

Other income and expenses increased by $15,074 from $161,357 for the nine months ended September 30, 2023, to $176,431 for the nine months ended September 30, 2024.

The increase in interest income resulted from interest rate increases.

The following table summarizes our cash flows from operating and financing activities:

Nine Months Ended September 30,

and Development Expenses

and development expenses decreased by $0.3 million from $1.6 million for the three months ended March 31, 2024, to $1.3 million for the

three months ended March 31, 2025.

The decrease in research and development expenses resulted from $0.1 million of decreased clinical

expenses from the XYNGARI™ STAR-1 acne study, which completed enrollment during the fourth quarter of 2024, and $0.2 million of

decreased stock-based compensation resulting from the cancellation of out-of-the-money stock options during the first quarter of 2024.

and Administrative Expenses

and administrative expenses decreased by $0.5 million from $1.6 million for the three months ended March 31, 2024, to $1.1 million for

the three months ended March 31, 2025.

This decrease resulted from $0.3 million of decreased stock-based compensation resulting from

the cancellation of out-of-the-money stock options during the first quarter of 2024 and $0.2 million of decreased audit fees.

Income and Expenses

income decreased by $33,082 from $69,298 for the three months ended March 31, 2024, to $36,216 for the three months ended March 31, 2025.

The decrease in interest income resulted from decreased cash balances.

following table summarizes our cash flows from operating and financing activities:

Statements of cash flows data:

6 unchanged sentences

$ (6,557,698 )

Operating activities

Cash used in operations of $8.2 million for the nine months ended September 30, 2024, was the result of the net loss of $9.1 million, offset by increases in non-cash stock-based compensation of $0.6 million and increases in accrued expenses of $0.3 million.

Cash used in operations of $5.3 million for the nine months ended September 30, 2023, was the result of the net loss of $5.7 million, offset by non-cash stock-based compensation of $0.4 million.

Financing activities

Cash provided by financing activities of $7.0 million for the nine months ended September 30, 2024, was the result of the September 2024 PIPE financing which raised net proceeds of $3.1 million, sales of the Company’s shares through the ATM Agreement which raised net proceeds of $1.5 million during the third quarter of 2024, and the May 2024 warrant inducement financing which raised net proceeds of $2.3 million.

Cash provided by financing activities of $5.7 million for the nine months ended September 30, 2023, was the result of $4.2 million of net proceeds received from the issuance of Common Stock and warrants issued in the March 2023 Offering, as well as $1.5 million of net proceeds received from the May 2023 Offering.

Liquidity and Capital Resources

Since our inception, we have not generated any revenue or commercialized any products.

As of September 30, 2024, our cash and cash equivalents totaled $6.1 million, and we had an accumulated deficit of $62.5 million.

For the nine months ended September 30, 2024, and the year ended December 31, 2023, we used cash of $8.2 million and $6.4 million, respectively, in operations.

We expect our cash resources to fund operations into the second quarter of 2025.

$ (2,704,454 )

used in operations of $1.9 million for the three months ended March 31, 2025, was the result of the net loss of $2.3 million, offset

by increases in accounts payable and accrued expenses of approximately $0.3 million, as well as the decrease of prepaid expenses and

other current assets of approximately $0.1 million.

and cash equivalents used in operations of $2.7 million for the three months ended March 31, 2024, was the result of the net loss of

$3.1 million, offset by $0.6 million in non-cash stock-based compensation expense, a decrease in prepaid expenses and other current assets

of $0.1 million, and decreases in accounts payable and accrued and other current liabilities of $0.3 million.

provided by financing activities of $8.5 million for the three months ended March 31, 2025, was the result of the January 2025 PIPE financing

which raised net proceeds of $2.3 million, and the March 2025 Inducement financing which raised net proceeds of $6.2 million.

and Capital Resources

our inception, we have not generated any revenue or commercialized any products.

As of March 31, 2025, our cash and cash equivalents

totaled $9.7 million, and we had an accumulated deficit of $68.0 million.

For the three months ended March 31, 2025, and the year ended

December 31, 2024, we used cash of $1.9 million and approximately $11.1 million, respectively, in operations.

We expect our cash resources

to fund operations into the first quarter of 2026.

We anticipate that we will continue to incur net losses for the foreseeable future.

Historically, our principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds from the issuance of debt.

Our principal uses of cash have included cash used in operations (including clinical development of our product candidates and general and administrative expenses) and payments for license rights.

We expect that the principal uses of cash in the future will be for continuing operations, funding of research and development, and general working capital requirements.

We expect that as research and development expenses continue to grow, we will need to raise additional capital to sustain operations and research and development activities.

Funding Requirements

We plan to focus in the near term on the development, regulatory approval, and potential commercialization of DMT310 for the treatment of acne.

We anticipate we will incur net losses for the next several years as we complete clinical development of DMT310 for the treatment of acne and psoriasis and continue research and development of DMT410 for the treatment of aesthetic and medical skin conditions.

In addition, we plan to seek opportunities to identify, acquire or in license and develop additional drug candidates, potentially build commercial capabilities, and expand our corporate infrastructure.

We may not be able to complete the development and initiate commercialization of these programs if, among other things, our clinical trials are not successful or if the FDA does not approve our drug candidate arising out of our current clinical trials when we expect, or at all.

Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, clinical costs, external research and development services, legal and other regulatory expenses, and administrative and overhead costs.

Our future funding requirements will be heavily determined by the resources needed to support the development of our drug candidates.

As a publicly traded company, we will incur significant legal, accounting, and other expenses that we were not required to incur as a private company.

In addition, the Sarbanes-Oxley Act of 2002, as well as rules adopted by the Securities and Exchange Commission (the “SEC”), and Nasdaq, requires public companies to implement specified corporate governance practices that were not applicable to us as a private company.

We expect these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly.

We believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the second quarter of 2025.

We have based this estimate of cash runway on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.

Historically,

our principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds from the issuance

Our principal uses of cash have included cash used in operations (including clinical development of our product candidates and

general and administrative expenses) and payments for license rights.

We expect that the principal uses of cash in the future will be

for continuing operations, funding of research and development, and general working capital requirements.

We expect that as research

and development expenses continue to grow, we will need to raise additional capital to sustain operations and research and development

plan to focus in the near term on the development, regulatory approval, and potential commercialization of XYNGARI™ for the treatment

We anticipate we will incur net losses for the next several years as we complete clinical development of XYNGARI™ for

the treatment of acne and psoriasis and continue research and development of DMT410 for the treatment of aesthetic and medical skin conditions.

In addition, we plan to seek opportunities to identify, acquire or in license and develop additional drug candidates, potentially build

commercial capabilities, and expand our corporate infrastructure.

We may not be able to complete the development and initiate commercialization

of these programs if, among other things, our clinical trials are not successful or if the FDA does not approve our drug candidate arising

out of our current clinical trials when we expect, or at all.

primary uses of capital are, and we expect will continue to be, compensation and related expenses, clinical costs, external research

and development services, legal and other regulatory expenses, and administrative and overhead costs.

Our future funding requirements

will be heavily determined by the resources needed to support the development of our drug candidates.

believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements

into the first quarter of 2026.

We have based this estimate of cash runway on assumptions that may prove to be wrong, and we could utilize

our available capital resources sooner than we expect.

We anticipate that we will continue to incur net losses for the foreseeable future.

These factors raise substantial doubt about our ability to continue as a going concern for the one-year period following the date that these financial statements were issued.

We will require additional capital to complete the Phase 3 studies for DMT310 for the treatment of acne, continue development of DMT310, and to pursue in-licenses or acquisitions of other drug candidates.

Therefore, based on our recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable future, and the need to raise additional capital to finance future operations, we are developing plans to mitigate this risk, which may consist of raising additional capital through some combination of equity or debt financings, and/or potentially new collaborations, business transactions, and reducing cash expenditures.

If we are not able to secure adequate additional funding, we may be forced to make significant reductions in our operations and the pursuit of our growth strategy.

In that event, we may have to delay, scale back, or eliminate some or all of our research and development programs and activities which could adversely affect our business prospects, or we may be unable to continue operations.

We may raise additional capital through the sale of equity or convertible debt securities.

In such an event, the terms of these securities may include liquidation or other preferences that adversely affect the rights of the holders of our Common Stock.

Because of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical drugs, we are unable to estimate the exact amount of our working capital requirements.

Our future funding requirements will depend on many factors, including:

the number and characteristics of the drug candidates we pursue;

the scope, progress, results, and costs of researching and developing our drug candidates, and conducting preclinical studies and clinical trials;

the timing of, and the costs involved in, obtaining regulatory approvals for our drug candidates;

the cost of manufacturing our drug candidates and any drugs we successfully commercialize;

our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;

the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims, including litigation costs and the outcome of such litigation; and

the timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future drug candidates, if any.

To continue to grow our business over the longer term, we plan to commit substantial resources to research and development, clinical trials of our product candidates, and other operations and potential product acquisitions and in licensing.

We have evaluated and expect to continue to evaluate a wide array of strategic transactions as part of our plan to acquire or in license and develop additional products and product candidates to augment our internal development pipeline.

Strategic transaction opportunities that we may pursue could materially affect our liquidity and capital resources and may require us to incur additional indebtedness, seek equity capital or both.

In addition, we may pursue development, acquisition or in licensing of approved or development products in new or existing therapeutic areas or continue the expansion of our existing operations.

Accordingly, we expect to continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to expand our operations, or for general corporate purposes.

Strategic transactions may require us to raise additional capital through one or more public or private debt or equity financings or could be structured as a collaboration or partnering arrangement.

We have no arrangements, agreements, or understandings in place at the present time to enter into any acquisition, in licensing or similar strategic business transaction.

Contractual Obligations and Commitments

We do not currently own or lease any office space.

We enter into contracts in the normal course of business with contract research organizations for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes.

These contracts generally provide for termination upon notice, and therefore we believe that our non-cancelable obligations under these agreements are not material.

JOBS Act Accounting Election

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).

Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies.

We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Recent Accounting Pronouncements

See Item 1 of Part I, “Notes to Financial Statements — Note 2 — Summary of Significant Accounting Policies” for a discussion of recent accounting pronouncements.

These factors raise substantial doubt about our ability to continue as a going concern for the one-year period following the date that

these financial statements were issued.

We will require additional capital to complete the Phase 3 studies for XYNGARI™ for the

treatment of acne, continue development of XYNGARI™, and to pursue in-licenses or acquisitions of other drug candidates.

based on our recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable

future, and the need to raise additional capital to finance future operations, we are developing plans to mitigate this risk, which may

consist of raising additional capital through some combination of equity or debt financings, and/or potentially new collaborations, business

transactions, and reducing cash expenditures.

If we are not able to secure adequate additional funding, we may be forced to make significant

reductions in our operations and the pursuit of our growth strategy.

In that event, we may have to delay, scale back, or eliminate some

or all of our research and development programs and activities which could adversely affect our business prospects, or we may be unable

to continue operations.

may raise additional capital through the sale of equity or convertible debt securities.

In such an event, the terms of these securities

may include liquidation or other preferences that adversely affect the rights of the holders of our Common Stock.

of the numerous risks and uncertainties associated with research, development, and commercialization of pharmaceutical drugs, we are

unable to estimate the exact amount of our working capital requirements.

Our future funding requirements will depend on many factors,

number and characteristics of the drug candidates we pursue;

scope, progress, results, and costs of researching and developing our drug candidates, and conducting preclinical studies and clinical

timing of, and the costs involved in, obtaining regulatory approvals for our drug candidates;

cost of manufacturing our drug candidates and any drugs we successfully commercialize;

ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;

costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims, including litigation costs

and the outcome of such litigation; and

timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future drug candidates,

continue to grow our business over the longer term, we plan to commit substantial resources to research and development, clinical trials

of our product candidates, and other operations and potential product acquisitions and in licensing.

We have evaluated and expect to

continue to evaluate a wide array of strategic transactions as part of our plan to acquire or in license and develop additional products

and product candidates to augment our internal development pipeline.

Strategic transaction opportunities that we may pursue could materially

affect our liquidity and capital resources and may require us to incur additional indebtedness, seek equity capital or both.

we may pursue development, acquisition or in licensing of approved or development products in new or existing therapeutic areas or continue

the expansion of our existing operations.

Accordingly, we expect to continue to opportunistically seek access to additional capital to

license or acquire additional products, product candidates or companies to expand our operations, or for general corporate purposes.

Strategic transactions may require us to raise additional capital through one or more public or private debt or equity financings or

could be structured as a collaboration or partnering arrangement.

We have no arrangements, agreements, or understandings in place at

the present time to enter into any acquisition, in licensing or similar strategic business transaction.

Obligations and Commitments

do not currently own or lease any office space.

enter into contracts in the normal course of business with contract research organizations for clinical trials, preclinical research

studies and testing, manufacturing and other services and products for operating purposes.

These contracts generally provide for termination

upon notice, and therefore we believe that our non-cancelable obligations under these agreements are not material.

Act Accounting Election

are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).

JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the

JOBS Act until such time as those standards apply to private companies.

We have irrevocably elected not to avail ourselves of this exemption

from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public

companies that are not emerging growth companies.

Accounting Pronouncements

Item 1 of Part I, “Notes to Financial Statements — Note 2 — Summary of Significant Accounting Policies” for a

discussion of recent accounting pronouncements.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis